Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | PGC | P20142 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553819 | 1.00 | CTSB (0.48) | CTSBBACE1PSEN1PSEN2APH1B | |
| SCHEMBL6447570 | 0.86 | CTSB (0.66) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6447573 | 0.86 | CTSB (0.66) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3553186 | 0.86 | UGT1A1 (0.56) | CTSBCTSD | |
| SCHEMBL3553181 | 0.86 | UGT1A1 (0.56) | CTSBCTSD | |
| SCHEMBL9012913 | 0.80 | BACE1 (0.50) | BACE1SLC6A11BCHE | |
| SCHEMBL15958897 | 0.80 | PSEN1 (0.46) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3710561 | 0.80 | BACE1 (0.44) | CTSBBACE1PSEN1PSEN2APH1B | |
| SCHEMBL3507689 | 0.79 | CTSC (0.48) | BACE1SLC6A11BCHE | |
| SCHEMBL3507688 | 0.79 | CTSC (0.48) | BACE1SLC6A11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | CTSB 26/4885BACE1 112/4885PSEN1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.